ArticleBMC neurology2026
A case of isolated brainstem bright spotty lesion in a patient with AQP4-positive NMOSD.
Article in BMC neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNeuromyelitis optica spectrum disorder (NMOSD) is an autoimmune central nervous system disorder mainly associated with aquaporin-4 antibodies. While it primarily affects the optic nerves and spinal cord, brainstem involvement may occur. CASE PRESENTATION: A twenty-eight years old woman with medical background of anorexia nervosa and cutaneous neurofibromatosis, was referred to our center for progressive gait disorders with a tetrapyramidal syndrome. MRI revealed isolated T2-hyperintense lesions of the medullo-spinal junction, characterized by brighter spotty T2-hyperintense areas within it, known as bright spotty lesion, and showing heterogenous enhancement. Further investigations led to the diagnosis of AQP4 + Neuromyelitis Optical Spectrum Disorder. The clinical and radiological evolution were favorable after immunotherapy.
conclusionsOur case illustrates the variety of the NMO spectrum and alerts clinicians to evoke this diagnosis in front of insidious symptoms and rare radiological presentation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.